Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 89, Issue 2, 2003, Pages 267-270

  Rose, Peter G ^a,f   Blessing, John A ^b   Buller, Richard E ^c   Mannel, Robert S ^d   Webster, Kenneth D ^e  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ETOPOSIDE;

ADULT; AGED; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; HYPOCALCEMIA; HYPONATREMIA; INFECTION; INSOMNIA; LEUKOPENIA; LIVER FUNCTION; LUNG DISEASE; MAXIMUM PERMISSIBLE DOSE; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NON SQUAMOUS CELL CARCINOMA; PAIN; PHASE 2 CLINICAL TRIAL; PRESCRIPTION; PRIORITY JOURNAL; THROMBOCYTOPENIA; TINNITUS; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

EID: 0037404833     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00079-9     Document Type: Article

References (23)

1. Louvhivouri K. Effect of a mass screening program on the risk of cervical cancer. Cancer Detect Prev. 15:1991;471-475.
2. Nieminen P., Kallion M., Hakama M. The effect of mass screening on the incidence and mortality of squamous and adenocarcinoma of cervix uteri. Obstet Gynecol. 85:1995;1017-1021.
3. SEER Cancer Statistics Review 1973-1996 (NCI 1999).
4. Smith H.O., Tiffany M.F., Qualls C.R., Key C.R. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States a 24-year population-based study . Gynecol Oncol. 78:2000;97-105.
5. Bonomi P., Blessing J.A., Stehman F.B., DiSaia P.J., Walton L., Major F.J. Randomized trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix a Gynecologic Oncology Group study . J Clin Oncol. 3:1985;1079-1085.
6. Slevin M.L., Clark P.I., Joel S.P., Malik S., Osborne R.J., Gregory W.M., et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol. 7:1989;1333-1340.
7. Rose P.G., Blessing J.A., Mayer A.R., Homesley H.D. Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinoma a Gynecologic Oncology Group study . J Clin Oncol. 16:1998;405-410.
8. Slayton R.E., Creasman W.T., Petty W., Bundy B., Blessing J.A. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary a Gynecologic Oncology Group study . Cancer Treat Rep. 63:1979;2089-2092.
9. Slayton R.E., Blessing J.A., Homesley H.D. Phase II trial of etoposide in the management of advanced and recurrent non-squamous cell carcinoma of the cervix a Gynecologic Oncology Group study . Cancer Treat Rep. 68:1984;1513-1514.
10. Rose P.G., Blessing J.A., Van Lee L., Waggoner S. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix a Gynecologic Oncology Group study . Gynecol Oncol. 70:1998;263-266.
11. Curtin J.P., Blessing J.A., Webster K.D., Rose P.G., Mayer A., Fowler W.C., et al. Paclitaxel an active agent in adenocarcinoma of the uterine cervix: a Gynecologic Oncology Group study . J Clin Oncol. 19:2001;1275-1278.
12. McGuire W.P., Blessing J.A., Moore D., Lentz S.S., Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer a Gynecologic Oncology Group study . J Clin Oncol. 14:1996;792-795.
13. Rose P.G., Blessing J.A., Gershenson D.M., McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix a Gynecologic Oncology Group study . J Clin Oncol. 17:1999;2676-2680.
14. Moore D.H., McQuellon R.P., Blessing J.A., Thaler H., Benda J., Miller D.S., et al. A randomized phase III study of cisplatin versus cisplatin and paclitaxel in stage IV-B or persistent squamous cell carcinoma of the cervix a Gynecologic Oncology Group study . Proc Am Soc Clin Oncol. 20:2001;201a.
15. Morris M., Brader K.R., Levenback C., Burke T.W., Atkinson E.N., Scott W.R., Gershenson D.M. Phase II study of vinorelbhne in advanced and recurrent squalous cell carcinoma of the cervix. J Clin Oncol. 16:1998;1094-1098.
16. Schilder R.J., Blessing J.A., Morgan M., Mangan C.E., Rader R.S. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix a phase II study of the Gynecologic Oncology Group . Gynecol Oncol. 76:2000;204-207.
17. Bookman M.A., Blessing J.A., Hanjani P., Herzog T.J., Anderson W.A. Topotecan in squamous cell carcinoma of the cervix a phase II study of the Gynecologic Oncology Group . Gynecol Oncol. 77:2000;446-449.
18. Pignata S., Silvestro G., Ferrari E., Selvaggi L., Perrone F., Maffeo A., et al. Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. J Clin Oncol. 17:1999;756-760.
19. Burnett A.F., Roman L.D., Garcia A.A., Muderspach L.I., Brader K.R., Morrow C.P. A phase II study of gemcitabine and cisplatin in patients with advanced, persistent or recurrent squamous cell carcinoma of the cervix. Gynecol Oncol. 76:2000;63-66.
20. Fiorica J., Grendys E., Holloway R., et al. Phase II trial of topotecan combined with cisplatin in squamous and non-squamous cervical cancer preliminary results . Proc ASCO. 18:1999;373a.
21. Al-Saleh E., Hoskins P.J., Pike J.A., Swenerton K.D. Cisplatin/etoposide chemotherapy for recurrent or primarily advanced cervical carcinoma. Gynecol Oncol. 64:1997;468-472.
22. Miller A.A., Herndon J.E., Hollis D.R., Ellerton J. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small cell lung cancer a randomized phase II study of the Cancer and Leukemia Group B . J Clin Oncol. 13:1995;1871-1879.
23. Fukuoka M., Masuda N., Negoro S., Takada M., Kudoh S., Kusunoki Y., et al. A phase I study of chronic daily dosing of oral etoposide in combination with cisplatin for patients with advanced cancer. Cancer. 68:1991;284-288.